Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

Eli Lilly has filed lawsuits ... solutions for individual patient needs. The legal action also questions the safety of the compounded drugs and challenges whether the defendants are violating ...

Novo Nordisk and Eli Lilly , the leaders in the highly ... drug prices would be difficult to implement and face legal challenges. Roche boosts US presence with new $700 million North Carolina ...

We are maintaining Eli Lilly’s Uncertainty Rating ... encounters considerable regulatory and legal risks, including product approvals, patent challenges, and liability lawsuits.

Lilly sues four telehealth firms for unauthorized compounding of Mounjaro and Zepbound. 2. GLP 1 drugs remain in high demand ...

US President Donald Trump signed an executive order requiring drugmakers to lower prices, aligning with international rates.

Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo ...